1 company and 9 research reports found for "ArQule"
ArQule is a US biotech company engaged in development of small molecule drugs for cancer. Its lead p...
No sector reports have been found.
ArQulePharmaceutical & healthcare | 05/01/2016
Edison Investment Research is terminating coverage on ArQule (ARQL). Please note you should no longer rely on any previous research or estimates for t...
ArQulePharmaceutical & healthcare | 13/06/2014
Detailed data presented at ASCO 2014 on c-Met inhibitors, including Roche's onartuzumab and ArQule's tivantinib, failed to show much clinical benefit ...
ArQulePharmaceutical & healthcare | 14/03/2014
Roche’s recent decision to stop the Phase III METLung trial, which tested MetMab, an anti-Met antibody, for second-line non-small cell lung canc...
ArQulePharmaceutical & healthcare | 22/01/2014
The DMC's (Data Monitoring Committee) recommendation of continuation of the pivotal Phase III METIV-HCC trial in hepatocellular carcinoma (HCC) offici...
ArQulePharmaceutical & healthcare | 08/10/2013
Confirmation that tivantinib offers a statistically significant benefit in terms of progression-free and overall survival in high c-MET, NSCLC has bro...
ArQulePharmaceutical & healthcare | 01/08/2013
ArQule has made the inevitable reorganisation, by cutting 25 positions, to preserve cash (which now runs into 2016), prioritise investment into two ea...
ArQulePharmaceutical & healthcare | 19/03/2013
2013 will be a year in which ArQule and its partners are focused on progressing and/or completing clinical trials with tivantinib, but one which sees ...
ArQulePharmaceutical & healthcare | 15/01/2013
The failure of tivantinib to show a statistically significant increase in PFS in a Phase II trial in second-line metastatic colorectal cancer (mCRC) m...